Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Jul 05, 2022 11:24am
260 Views
Post# 34801946

Cleaning Up (2)

Cleaning Up (2)
Couple of things.
 
About the share price, it has no business being this low, not with the collaborations that Bioasis has going on. I don't think there's enough BTI volume to consider there to be a shareholder capitulation going on.

We could be seeing some malicious selling. There are shareholders whose methods of expressing anxiety and disappointment are to try to cause damage to the company and its shareholders. That's how trolls operate. Selling some shares to drive the share price down when the opportunity is presented can be an extension of troll-like behaviour. 
 
If somebody is trying to set a low price for a financing then Bioasis may be able to exercise the Lind Partners funding agreement to get some operational runway. This may allow the company to get through until the company or its partners generate some news that could lift the share price. I would question the company if there is a financing of any size below 20¢. 

I am not spending time on Bioasis as Finallytherock alleges. I do not read scientific papers anymore. I follow a couple of pharma and biotech news sources but that's ten or fifteen minutes of work per day. I get a lot of news from automated searches. I'll report here or somewhere else anything that shareholders ought to know.
 
What I am spending time on is my new project that is completely unrelated to the stock market and science/medicine. And I'm spending time on some legal things relating to new and previous activities.
 
jd
<< Previous
Bullboard Posts
Next >>